醛固酮合酶抑制剂:治疗肾脏与心血管疾病的新契机
醛固酮过量参与多种心血管、内分泌及肾脏疾病的病理生理过程。盐皮质激素受体拮抗剂(MRA)虽被推荐用于这些疾病,但螺内酯的性相关不良反应及肾功能减退患者的高钾血症风险限制其使用,而依普利酮选择性更高但效力弱于螺内酯。醛固酮合酶抑制剂(ASI)作为潜在替代方案,早期II期试验显示其可降低未控制高血压患者的血压及蛋白尿性慢性肾脏病患者的尿白蛋白排泄。
要点
- 螺内酯因缺乏盐皮质激素受体特异性而致性相关不良反应,且肾功能减退者高钾血症风险限制其使用。
- 依普利酮选择性更高,但效力弱于螺内酯。
- 新型ASI在人体大剂量范围内对CYP11B2显示高选择性,有效减少醛固酮生成而不影响皮质醇合成。
核心结论
- ASI已作为MRA的潜在替代方案出现,早期II期试验显示其可降低未控制高血压患者的血压及蛋白尿性慢性肾脏病患者的尿白蛋白排泄。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 螺内酯因缺乏盐皮质激素受体特异性而致性相关不良反应,且肾功能减退患者存在高钾血症风险,限制其使用。
- 依普利酮是选择性更高的MRA,但效力弱于螺内酯。
- 新型非甾体MRA虽有前景,但全球不可及或仍在开发中。
- 醛固酮介导基因组与非基因组效应,后者不能被MRA完全阻断。
- 新型ASI在体外及体内对CYP11B2显示高选择性,在人体大剂量范围内有效减少醛固酮生成而不影响皮质醇合成。
局限性
- 选择性ASI的开发具有挑战性,因醛固酮合成最终步骤(由肾上腺皮质球状带CYP11B2介导)与皮质醇合成(由束状带CYP11B1介导)高度同源。
- 需进一步开展更长期试验,评估其单独或与SGLT2抑制剂联用时降低血压、减少肾脏病进展及改善心力衰竭心血管结局的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inappropriate aldosterone excess plays a key role in the pathophysiology of various cardiovascular, endocrine, and renal diseases. Mineralocorticoid receptor antagonists (MRAs) such as spironolactone block of the harmful effects of aldosterone and are recommended treatment in these various conditions. However, the sexual adverse effects of spironolactone from its lack of specificity for the mineralocorticoid receptor and the risk of hyperkalemia in patients with decreased renal function, limit its use. While eplerenone is a more selective MRA, it is less potent than spironolactone. Newer nonsteroidal MRAs, though promising, are either unavailable globally or still under development. Moreover, aldosterone exerts both genomic and nongenomic effects, the latter not fully blocked by MRAs. Aldosterone synthase inhibitors (ASIs) have thus emerged as potential alternatives to MRAs, though the development of selective ASIs has been challenging. This is due to the close homology between the final step of aldosterone synthesis, mediated by CYP11B2 in the zona glomerulosa of the adrenal cortex, and cortisol synthesis, mediated by CYP11B1 in the zona fasciculata. Despite these challenges, new ASIs have demonstrated high in vitro as well as in vivo selectivity for CYP11B2, effectively reducing aldosterone production without affecting cortisol synthesis in humans across large dose ranges. Early phase II trials demonstrated that these ASIs decrease (1) blood pressure in uncontrolled hypertension and (2) urinary albumin excretion in proteinuric chronic kidney disease. Further longer term trials will evaluate their efficacy in lowering blood pressure as well as in reducing kidney disease progression and cardiovascular outcomes in heart failure when given alone or in combination with SGLT2 inhibitors.
引用
- Azizi M, Riancho J, Amar L, et al. Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases. J Clin Endocrinol Metab. 2025. PMID: 39656736. doi:10.1210/clinem/dgae823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。